

# Paroxysmal nocturnal haemoglobinuria – eculizumab or ravulizumab – initial grandfather authority application

## Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

For more information and how to access the **Online PBS Authorities** system, go to [servicesaustralia.gov.au/hppbsauthorities](https://servicesaustralia.gov.au/hppbsauthorities)

## When to use this form

Use this form to apply for **initial grandfather** PBS-subsidised eculizumab or ravulizumab for patients with paroxysmal nocturnal haemoglobinuria (PNH) who had, prior to **1 March 2022**:

- received non-PBS-subsidised treatment with eculizumab or ravulizumab – maintenance phase
- received eculizumab through the Australian Government's Life Saving Drugs Program (LSDP) and are continuing on eculizumab.

## Important information

**Initial grandfather** applications to start PBS-subsidised treatment can be made using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for PNH **initial grandfather** authority applications.

Complement 5 (C5) inhibitors are defined as eculizumab or ravulizumab.

The information in this form is correct at the time of publishing and may be subject to change.

## Continuing treatment

This form is ONLY for **initial grandfather** treatment.

For **continuing** PBS-subsidised treatment, the patient must qualify under the **first continuing** or **subsequent continuing** treatment criteria.

## Section 100 arrangements for eculizumab and ravulizumab

These items are available to a patient who is attending:

- an approved private hospital, **or**
- a public hospital

**and** is a:

- day admitted patient
- non-admitted patient, **or**
- patient on discharge.

These items are not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

## For more information

Go to [servicesaustralia.gov.au/healthprofessionals](https://servicesaustralia.gov.au/healthprofessionals)

# Paroxysmal nocturnal haemoglobinuria – eculizumab or ravulizumab – initial grandfather authority application

## Online PBS Authorities



You do not need to complete this form if you use the  
**Online PBS Authorities** system.

Go to [servicesaustralia.gov.au/hppbsauthorities](https://servicesaustralia.gov.au/hppbsauthorities)

## Patient's details

**1** Medicare card number

Ref no.

or

Department of Veterans' Affairs card number

**2** Family name

First given name

**3** Date of birth (DD MM YYYY)

**4** Patient's current weight

 kg

## Prescriber's details

**5** Prescriber number

**6** Family name

First given name

**7** Business phone number (including area code)

Alternative phone number (including area code)

## Hospital details

**8** Hospital name

This hospital is a:

☐ public hospital

☐ private hospital

**9** Hospital provider number

## Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

**10** The patient is being treated by a:

☐ haematologist

☐ non-specialist medical physician who has consulted a haematologist

**11** This application is for:

☐ eculizumab **▶ Go to 12**

☐ ravulizumab **▶ Go to 14**

**12** The patient:

☐ has received non-PBS-subsidised treatment with eculizumab for this condition prior to 1 March 2022

or

☐ has previously received eculizumab for the treatment of this condition funded under the Australian Government's LSDP.

**13** Has the patient experienced clinical improvement or a stabilisation of the condition as a result of treatment with this drug?

Yes ☐ **▶ Go to 16**

No ☐

**14** Has the patient received non-PBS-subsidised treatment with ravulizumab for this condition prior to 1 March 2022?

Yes ☐

No ☐



MCA0PB329 2506

**15** Has the patient demonstrated clinical improvement or stabilisation of the condition with details kept with the patient's record?

Yes ☐  
No ☐

**16** Is this treatment in combination with another C5 inhibitor or pegcetacoplan?

Yes ☐  
No ☐

**17** Prior to commencing treatment with this drug, the patient had:

☐ a diagnosis of PNH established by flow cytometry

and

☐ a PNH granulocyte clone size  $\geq 10\%$

and

☐ a raised lactate dehydrogenase (LDH) value at least 1.5 times the upper limit of normal (ULN).

**18** Prior to commencing treatment with this drug, the patient had:

☐ experienced a thrombotic/embolic event which required anticoagulant therapy

or

☐ been transfused with at least 4 units of red blood cells in the previous 12 months

or

☐ debilitating shortness of breath/chest pain resulting in limitation of normal activity (New York Heart Association Class III) and/or established diagnosis of pulmonary arterial hypertension, where causes other than PNH had been excluded

or

☐ a history of renal insufficiency, demonstrated by an eGFR  $\leq 60$  mL/min/1.73m<sup>2</sup>, where causes other than PNH had been excluded

or

☐ recurrent episodes of severe pain requiring hospitalisation and/or narcotic analgesia where causes other than PNH had been excluded

or

☐ chronic/recurrent anaemia, where causes other than haemolysis had been excluded, together with multiple haemoglobin measurements:

☐ not exceeding 70 g/L in the absence of anaemia symptoms

or

☐ not exceeding 100 g/L in addition to having anaemia symptoms.

**19** Provide details of the following monitoring requirements

Test	Result	Date of test (DD MM YYYY)			
Haemoglobin (g/L)					
Platelets (x10 <sup>9</sup> /L)					
White Cell Count (x10 <sup>9</sup> /L)					
Reticulocytes (x10 <sup>9</sup> /L)					
Neutrophils (x10 <sup>9</sup> /L)					
Granulocyte clone size (%)					
LDH					
ULN for LDH as quoted by the reporting laboratory					
LDH : ULN ratio (in figures, rounded to one decimal place & must be at least 1.5)					

## Checklist

**20**  The relevant attachments need to be provided with this form.

☐ Details of the proposed prescription(s).

## Privacy notice

**21** Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application. Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at [servicesaustralia.gov.au/privacypolicy](https://servicesaustralia.gov.au/privacypolicy)

## Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at **servicesaustralia.gov.au/hpos**

### 22 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

### I understand that:


- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)


---

## Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at **servicesaustralia.gov.au/hpos**  
**or**
- by post (signature required) to  
Services Australia  
Complex Drugs Programs  
Reply Paid 9826  
HOBART TAS 7001